Celltrion grants distribution rights for biosimilar agent Herzuma in several EU countries

South Korean firm Celltrion Healthcare (Kosdaq: 068270) has granted exclusive distribution rights to its trastuzumab biosimilar, Herzuma,in seven European Union markets including Germany, Italy and the UK, to the Mundipharma global network of independent associated companies. No financial terms of the deal have been disclosed.

Man Hoon Kim, president and chief executive of Celltrion Healthcare, commented: “We are pleased to be partnering once again with Mundipharma on the commercialization of our trastuzumab biosimilar. They have a proven track record of launching biosimilars in Europe, working effectively across multiple healthcare systems and demonstrating local in-market expertise. This alliance enables us to continue to pursue our commitment to delivering effective and affordable medicines which benefit healthcare systems, healthcare professionals and patients.”

“Celltrion Healthcare’s decision to entrust us with a third biosimilar from their portfolio is testament to the insight and experience we have developed from successfully launching two previous monoclonal antibody biosimilars. With Remsima (infliximab) we achieved market leading status in the majority of our markets, and we are already seeing strong market uptake with our newest biosimilar medicine Truxima (rituximab) across those markets where we have distribution rights, commented Richard Trollope, commercial head of oncology and biosimilars at Mundipharma. “We look forward to, once again, using our expertise in biosimilars to navigate the complex European environment and enable Herzuma to help healthcare economies deliver better value to patients,” he added.